Clinical Trials Directory

Trials / Sponsors / Ludwig Institute for Cancer Research

Ludwig Institute for Cancer Research

Academic / Other · 51 registered clinical trials.

StatusTrialPhaseStarted
CompletedPhase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NS
Metastatic Non-small Cell Lung Cancer, NSCLC
Phase 1 / Phase 22017-12-20
CompletedA Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignanc
Colorectal Cancer, Ovarian Cancer, Appendiceal Cancer
Phase 1 / Phase 22017-09-07
CompletedPhase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer
Non-small Cell Lung Cancer, Carcinoma, NSCLC
Phase 1 / Phase 22017-05-10
CompletedA Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma
Phase 1 / Phase 22016-12-28
TerminatedPhase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant
Multiple Myeloma
Phase 12016-12-13
CompletedPilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV
Melanoma
Phase 12016-10-13
CompletedStudy of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Esophageal Cancer
Phase 1 / Phase 22016-06-24
CompletedPhase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer
Ovarian Cancer
Phase 1 / Phase 22015-12-02
CompletedPhase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma
Glioblastoma
Phase 22015-02-26
CompletedSafety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers
Malignant Solid Tumor, Metastatic EphA2 Positive Cancer
Phase 12014-12-09
TerminatedPhase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Me
Metastatic Melanoma
Phase 12014-03-01
WithdrawnStudy of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma
Metastatic Melanoma
Phase 1 / Phase 22014-03-01
TerminatedNY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Unresectable or Metastatic Melanoma
Phase 12014-01-24
CompletedA Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
Breast Cancer, Ovarian Cancer, Colorectal Cancer
Phase 12013-12-19
WithdrawnSingle Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphom
Solid Tumors, Lymphomas
Phase 12013-01-01
CompletedMAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transpla
Multiple Myeloma
Phase 12011-09-01
TerminatedStudy of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
Small Cell Lung Cancer
Phase 22011-01-01
CompletedA Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer
Colorectal Neoplasms
Phase 12010-10-12
CompletedVaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Phase 12008-11-14
CompletedPhase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma
Metastatic Melanoma, Cutaneous Melanoma
Phase 22008-03-28
CompletedPhase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Ca
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Phase 12008-03-01
TerminatedStudy of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma
Renal Cell Carcinoma (RCC)
Phase 12008-02-01
CompletedStudy of ADI-PEG 20 in Patients With Advanced Melanoma
Metastatic Melanoma, Skin Cancer, Neoplasm
Phase 1 / Phase 22007-07-01
CompletedA Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
Melanoma, Sarcoma, Gastrointestinal Stromal Tumor (GIST)
Phase 12007-05-01
CompletedNY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors
Tumors
Phase 12006-03-21
TerminatedBiodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen
Neoplasms
Phase 12006-02-01
CompletedStudy of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma
Melanoma
Phase 22005-09-01
CompletedNY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
Malignant Melanoma
Phase 12005-08-24
CompletedTreatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric
Renal Cell Carcinoma, Kidney Neoplasm, Renal Cancer
Phase 12005-07-06
CompletedSafety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers
Esophageal Cancer, Lung Cancer, Stomach Cancer
Phase 12005-07-01
TerminatedA Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma
Synovial Sarcoma
Phase 22005-06-08
CompletedSafety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.
Cancer of Kidney, Kidney Cancer, Renal Cancer
Phase 12005-06-01
Completed111In-ch806 in Patients With Advanced Tumours Expressing the 806 Antigen
Neoplasms
Phase 12005-05-01
CompletedPhase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer
Colorectal Cancer
Phase 12005-04-18
CompletedPhase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer
Metastatic Renal Cell Carcinoma
Phase 1 / Phase 22005-02-01
TerminatedImmunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma
Malignant Melanoma
Phase 1 / Phase 22005-01-12
TerminatedImmunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Mela
Malignant Melanoma
Phase 1 / Phase 22005-01-01
CompletedVaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Phase 22004-12-01
CompletedImmunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer
Prostate Cancer
Phase 12004-10-27
CompletedNY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
Prostate Cancer, Bladder Cancer, Non-small Cell Lung Cancer
Phase 12004-09-27
CompletedMonoclonal Antibody Therapy in Treating Patients With Progressive Small Cell Lung Cancer (SCLC)
Lung Cancer
Phase 12004-07-26
CompletedSafety Study of NY-ESO-1 Protein Vaccine to Treat Cancer Expressing NY-ESO-1
Neoplasms
Phase 12004-06-01
CompletedStudy of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma
Melanoma
Phase 22003-11-28
CompletedRadiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer
Ovarian Cancer
Phase 12003-11-01
CompletedVaccine Therapy in Treating Patients With Transitional Cell Carcinomas
Transitional Cell Carcinoma
Phase 12003-10-28
CompletedCapecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer
Colorectal Neoplasms
Phase 12003-10-01
CompletedA Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer.
Cancer, Neoplasm
Phase 12003-09-03
CompletedVaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Phase 12003-06-23
TerminatedMonoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer
Ovarian Cancer
Phase 12000-08-02
TerminatedMonoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer
Colorectal Cancer
Phase 12000-07-12
CompletedMonoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
Kidney Cancer
Phase 1 / Phase 21998-11-17